INVESTOR CLASS ACTION: RxSight, Inc. Investors are Reminded of the Ongoing Securities Fraud Lawsuit after Stock Plummeted 38% -- Contact BFA Law

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, specifically related to undisclosed challenges in product adoption and subsequent revenue forecast cuts [1][2][4]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. - The case is currently pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price following the announcement of a reduced revenue forecast on April 3, 2025, with shares dropping approximately 38% from $26.12 to $16.21 [5]. - A further revenue forecast cut on July 8, 2025, led to another 38% decline in stock price, from $12.79 to $7.95, attributed to slower LAL utilization and adoption challenges [6].